LY3549492の2型糖尿病（T2D）患者および健康な日本人被験者を対象とした試験

基本情報

NCT ID: NCT06869018
ステータス: 実施中（募集終了）
試験のフェーズ: 第1相
試験タイプ: 介入
目標被験者数: 90
治験依頼者名: Eli Lilly and Company

概要

The purpose of this study is to evaluate how well LY3549492 is tolerated and what side effects may occur in Japanese participants with Type 2 Diabetes Mellitus (T2D) and healthy Japanese participants. The study drug will be administered orally. Blood tests will be performed to check how much LY3549492 gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 19 weeks for both Part A (Cohorts 1-3) for multiple-ascending doses (MAD), and Part B (Cohorts 4-5) multiple-ascending doses (MAD), for a total of approximately 25 weeks, including screening.

対象疾患

HealthyType 2 Diabetes Mellitus (T2D)

介入

LY3549492(DRUG)

Placebo(DRUG)

依頼者（Sponsor）

日本イーライリリー株式会社(INDUSTRY)

実施施設 (4)

医療法人平心会　大阪治験病院

Osaka, Japan

一般社団法人　ＩＣＲ　附属　クリニカルリサーチ東京病院

Shinjuku-ku, Japan

P-One Clinic

Hachiōji, Japan

博多診療所

Fukuoka, Japan